产品
编 号：F000492
分子式：C25H43NaO6S
分子量：494.66
分子式：C25H43NaO6S
分子量：494.66
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1000403-03-1
产品详情
生物活性：
INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC50s of 30 and 630 nM, respectively.
体内研究：
INT-767 (10-20 mg/kg; i.p.; daily for 2 weeks) decreases plasma total cholesterol and triglyceride levels in db/m and db/db mice .Animal Model:Male 8-week old C57BKS/J db/db mice, control nondiabetic db/m mice
Dosage:10, 20 mg/kg
Administration:Intraperitoneal injection; daily for 2 weeks
Result:Decreased plasma total cholesterol and triglyceride levels.
体外研究：
INT-767 does not show cytotoxic effects in HepG2 cells, does not inhibit cytochrome P450 enzymes, is highly stable to phase I and II enzymatic modifications, and does not inhibit the human ether-a-go-go-related gene potassium channel.
INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC50s of 30 and 630 nM, respectively.
体内研究：
INT-767 (10-20 mg/kg; i.p.; daily for 2 weeks) decreases plasma total cholesterol and triglyceride levels in db/m and db/db mice .Animal Model:Male 8-week old C57BKS/J db/db mice, control nondiabetic db/m mice
Dosage:10, 20 mg/kg
Administration:Intraperitoneal injection; daily for 2 weeks
Result:Decreased plasma total cholesterol and triglyceride levels.
体外研究：
INT-767 does not show cytotoxic effects in HepG2 cells, does not inhibit cytochrome P450 enzymes, is highly stable to phase I and II enzymatic modifications, and does not inhibit the human ether-a-go-go-related gene potassium channel.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备